HC Wainwright Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $13.00

Unicycive Therapeutics (NASDAQ:UNCY) had its target price trimmed by HC Wainwright from $15.00 to $13.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at $0.04 EPS, FY2027 earnings at ($0.86) EPS, FY2028 earnings at $2.85 EPS, FY2029 earnings at $3.75 EPS and FY2030 earnings at $4.98 EPS.

A number of other brokerages also recently commented on UNCY. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Benchmark reiterated a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Finally, Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.25.

Unicycive Therapeutics Trading Down 3.2%

Shares of NASDAQ UNCY opened at $4.55 on Tuesday. Unicycive Therapeutics has a one year low of $3.93 and a one year high of $8.74. The firm has a market capitalization of $126.72 million, a PE ratio of -2.60 and a beta of 1.83. The business has a 50-day moving average price of $5.12 and a two-hundred day moving average price of $6.27.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41. Research analysts anticipate that Unicycive Therapeutics will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UNCY. Dimensional Fund Advisors LP acquired a new position in Unicycive Therapeutics in the 1st quarter valued at $940,000. Seven Fleet Capital Management LP boosted its holdings in Unicycive Therapeutics by 85.6% during the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after acquiring an additional 47,700 shares during the period. Bank of New York Mellon Corp bought a new stake in Unicycive Therapeutics during the second quarter valued at about $248,000. Bank of America Corp DE grew its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Unicycive Therapeutics in the first quarter valued at about $161,000. Institutional investors own 40.42% of the company’s stock.

Key Stories Impacting Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $13 price target, substantially above Unicycive’s recent trading level. The firm raised several longer-term EPS forecasts, including estimates of $2.85 for fiscal 2028, $3.75 for 2029 and $4.98 for 2030, reflecting expectations for improving commercialization and profitability. Some near-term quarterly and fiscal estimates were also improved, although the company is still expected to post losses through fiscal 2027. HC Wainwright earnings estimates
• Neutral Sentiment: Unicycive appointed Meredith Manning, M.B.A., to its board of directors. The addition may strengthen the company’s governance and strategic expertise, but the announcement provided no immediate change to the company’s clinical, regulatory or financial outlook. Unicycive appoints Meredith Manning
• Negative Sentiment: Multiple law firms publicized a securities class action against Unicycive and certain officers, with a November 2, 2026 deadline for investors to seek lead-plaintiff status. The allegations concern the company’s use of a contract manufacturer that had been cited by the FDA for current good manufacturing practice deficiencies, allegedly without confirming compliance. The lawsuit claims the unresolved issues contributed to a second Complete Response Letter and a reported 39.1% one-day share-price decline. These are allegations and have not been proven in court. Unicycive shareholder class action alert
• Negative Sentiment: HC Wainwright’s separate report reduced its Q1 2027 EPS forecast to a $0.43 loss from a $0.31 loss, and another report indicated the firm cut its price target, adding a modestly negative near-term signal despite the continued Buy rating.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.